In this sample 47.5% (n = 38) of subjects were ANA positive A greater recruitment effort was focused on FDRs, due to their known increased risk for developing SLE over that of the general population and therefore the relevance of ANA positivity as a potential biomarker predictive of future progression from silent autoimmunity to clinically significant autoimmune disease. The gene discussed is BTG3; the disease is systemic lupus erythematosus.